Sequence and structure-based peptides as potent amyloid inhibitors: A review

Area of Science:

• Biochemistry
• Neuroscience
• Molecular Biology

Background:

• Amyloid fibrils are protein aggregates characteristic of amyloidosis, including Alzheimer's, type 2 diabetes, and Parkinson's disease.
• Proteins like Amyloid-Beta (Aβ), human Islet Amyloid Polypeptide (hIAPP), and α-synuclein aggregate into fibrils, causing distinct degenerative disorders.
• Therapeutic strategies are challenging due to the lack of sequence/structural homology in native proteins, despite similar fibril structures.

Purpose of the Study:

• To review the inhibitory potential of small peptides against amyloidogenesis.
• To analyze both sequence-based and structure-based peptide inhibitors.
• To focus on peptides inhibiting the aggregation of Aβ, hIAPP, and α-synuclein.

Main Methods:

• Literature review of studies on peptide inhibitors of amyloidogenesis.
• Analysis of sequence-based peptide design principles.
• Evaluation of structure-based peptide design strategies.

Main Results:

• Rationally designed small peptides demonstrate potent inhibitory effects on amyloid fibril formation.
• Peptides can disrupt fibril structure by specifically binding to amyloidogenic regions.
• Both sequence and structure-based peptides show promise in inhibiting the aggregation of key disease-related proteins.

Conclusions:

• Small peptides represent a promising therapeutic avenue for treating amyloidosis.
• Targeting amyloidogenic regions with designed peptides can effectively inhibit protein aggregation.
• Further research into peptide-based inhibitors could lead to novel treatments for neurodegenerative and metabolic diseases.